Logo

Henlius Receives the NMPA's Approval for HLX03 (biosimilar- adalimumab) to Treat Autoimmune Disease

Share this

Henlius Receives the NMPA's Approval for HLX03 (biosimilar- adalimumab) to Treat Autoimmune Disease

Shots:

  • NMPA has approved HLX03 for the treatment of RA- AS and PsO. It is the first China-developed biosimilar- approved both in China and in the EU
  • The approval marks the expansion of the Henlius’ commercial pipeline into the field of autoimmune diseases and the scope of patients befitted with the therapy
  • Henlius will continue optimizing and upgrading the product- and cooperating with Wanbang Biopharma to promote the commercialization of biosimilar- to bring the high-quality treatment options to patients suffering from autoimmune diseases

 ­ Ref: Henlius | Image: Henlius

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions